What is ADMA Biologics's paid-in-kind interest capitalized?

ADMA Biologics (ADMA) reported paid-in-kind interest capitalized of $0 in Q4 2025.

What is the long-term trend for ADMA Biologics's paid-in-kind interest capitalized?

Over 2 years (2023 to 2025), ADMA Biologics's paid-in-kind interest capitalized has grown at a -100.0% compound annual growth rate (CAGR), from $3.84M to $0.

What does paid-in-kind interest capitalized mean?

This metric tracks interest expense that is settled by increasing the principal amount of a debt obligation rather than through cash payments. It is a critical indicator of debt structure and the company's reliance on non-cash financing to manage interest burdens.

ADMA Biologics ADMA Paid-in-kind interest capitalized

Paid-in-kind interest capitalized at other companies

DJT

Trump Media & Technology GroupDJT

$11.47M+6,040%

HTF

Heartflow, Inc. Common StockHTFL

$36K—

ADMA BiologicsADMA

$0—

Oruka Therapeutics, Inc.ORKA

$1.47M—

Eos Energy Enterprises, Inc.EOSE

$1.1M+39.7%

SBA CommunicationsSBAC

$772K-90.8%

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:PaidInKindInterest.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's paid-in-kind interest capitalized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's paid-in-kind interest capitalized?: ADMA Biologics (ADMA) reported paid-in-kind interest capitalized of $0 in Q4 2025.
What is the long-term trend for ADMA Biologics's paid-in-kind interest capitalized?: Over 2 years (2023 to 2025), ADMA Biologics's paid-in-kind interest capitalized has grown at a -100.0% compound annual growth rate (CAGR), from $3.84M to $0.
What does paid-in-kind interest capitalized mean?: This metric tracks interest expense that is settled by increasing the principal amount of a debt obligation rather than through cash payments. It is a critical indicator of debt structure and the company's reliance on non-cash financing to manage interest burdens.